Trial Profile
Study of Apremilast and Methotrexate monotherapy on Patients with Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Apremilast (Primary) ; Disease-modifying antirheumatics; Hydroxychloroquine; Leflunomide; Methotrexate; Sulfasalazine; Tofacitinib
- Indications Psoriatic arthritis; Spondylarthritis
- Focus Therapeutic Use
- 15 Apr 2021 Results comparing patient characteristics and disease burden between men and women with axial spondyloarthritis, published in The Journal of Rheumatology
- 15 Nov 2020 Results (n=150) of exploratory analysis evaluating whether apremilast monotherapy is an effective treatment option for oligoarticular PsA, published in The Journal of Rheumatology
- 06 Jun 2020 Results (N=119), assessing trends in characteristics of patients starting apremilast from 2014-2019 and compare characteristics of treatment naive patients, presented at the 21st Annual Congress of the European League Against Rheumatism